This chapter examines the growth of the biotechnology sector in Cuba. It explores Cuba's various attempts to define its biotechnology and its efforts to maintain a space for that science amid a rather differently couched global pharmaceutical norm. It mentions that the Center for Molecular Immunology's (CIM) TheraCIM drug was granted a U.S. patent in 1999 and an in-depth article on the CIM–York Medical partnership was featured in the July 2000 issue of Journal of the National Cancer Institute.
Chicago Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.
If you think you should have access to this title, please contact your librarian.
To troubleshoot, please check our FAQs, and if you can't find the answer there, please contact us.